URB602 is primarily used in research settings to study the endocannabinoid system, particularly as a selective inhibitor of monoacylglycerol lipase (MAGL). By inhibiting MAGL, it increases the levels of 2-arachidonoylglycerol (2-AG), an endogenous cannabinoid, in the brain. This makes it a valuable tool for investigating the role of 2-AG in various physiological processes, such as pain modulation, neuroinflammation, and synaptic plasticity. Researchers also explore its potential therapeutic applications in conditions like chronic pain, neurodegenerative diseases, and mood disorders. However, its use is currently limited to preclinical studies, and further research is needed to determine its efficacy and safety in humans.